3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
562
Carcinoma, Non-Small-Cell Lung
482
Ovarian Neoplasms
326
Lung Neoplasms
203
Fallopian Tube Neoplasms
152
Neoplasms
150
Triple Negative Breast Neoplasms
125
Esophageal Neoplasms
125
Stomach Neoplasms
121
Neoplasm Metastasis
119
Carcinoma, Ovarian Epithelial
114
Endometrial Neoplasms
95
Squamous Cell Carcinoma of Head and Neck
94
Uterine Cervical Neoplasms
79
Head and Neck Neoplasms
77
Esophageal Squamous Cell Carcinoma
77
Recurrence
48
Adenocarcinoma of Lung
47
Parkinson Disease 4, Autosomal Dominant Lewy Body
45
Melanoma
42
Carcinoma
42
Urinary Bladder Neoplasms
41
Adenocarcinoma Of Esophagus
36
Small Cell Lung Carcinoma
34
Carcinoma, Squamous Cell
34
Prostatic Neoplasms
31
Pancreatic Neoplasms
29
Breast Neoplasms, Male
28
Unspecified Adult Solid Tumor, Protocol Specific
27
Colorectal Neoplasms
25
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Paclitaxel
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts